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Abstract
Background: The diagnosis of lymph node metastasis in esophageal cancer by the presence and number of 
metastatic lymph nodes is an extremely important prognostic factor. In addition, the indication of non-surgical therapy 
is gaining more attention. Vascular endothelial growth factor C (VEGF-C) is potentially lymphangiogenic and selectively 
induces hyperplasia of the lymphatic vasculature. In this study, we investigated the expression of VEGF-C and whether 
it correlated with various clinico-pathologic findings.
Methods: KYSE series of esophageal cancer cell lines and 106 patients with primary esophageal squamous cell 
carcinomas who had undergone radical esophagectomy were analyzed. VEGF-C mRNA expression was determined by 
quantitative RT-PCR.
Results: High expression of VEGF-C was detected in most of the KYSE cell lines, especially KYSE410, yet, in an 
esophageal normal epithelium cell line, Het-1A, VEGF-C was not detected. In the clinical specimen, the expression of 
VEGF-C in the cancerous tissue was higher than in the corresponding noncancerous esophageal mucosa (p = 0.026). 
The expression of VEGF-C was found to be higher in Stage2B-4A tumors than in Stage0-2A tumors (p = 0.049). When 
the patients were divided into two groups according to their expression levels of VEGF-C (a group of 53 cases with high 
expression and a group of 53 cases with low expression), the patients with high VEGF-C expression had significantly 
shorter survival after surgery than the patients with low expression (p = 0.0065). Although univariate analysis showed 
that high expression of VEGF-C was a statistically significant prognostic factor, this was not shown in multivariate 
analysis. In the subgroup of patients with Tis and T1 tumors, the expression of VEGF-C was higher in N1 tumors than in 
N0 tumors (p = 0.029). The survival rate of patients from the high expression group (n = 10) was lower than that in the 
low expression group (n = 11), and all the patients in the low VEGF-C expression group survived.
Conclusions: The expression of VEGF-C correlates with lymph node metastasis and poor prognosis. In patients with Tis 
and T1 esophageal tumors, the expression of VEGF-C may be a good diagnostic factor for determining metastasis of 
the lymph node.
Background
Esophageal cancer is a disease with poor prognosis. Of
many prognostic factors, the metastatic lymph nodes are
one of the most significant. To avoid highly invasive sur-
gery, endoscopic mucosal resection (EMR), endoscopic
submucosal dissection (ESD), chemoradiotherapy, and
their combinations have been suggested for patients with
early esophageal cancer. When applying these non-surgi-
cal treatments, preoperative diagnosis of tumor invasion
and lymph node metastasis becomes especially impor-
tant. Unfortunately, computed tomography (CT) and
positron emission tomography (PET) are unable to diag-
nose lymph node metastasis accurately. In order to
develop plans for new diagnoses and treatment, it is
essential that the biological behavior of esophageal cancer
be understood. Recent studies have revealed that several
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genes and molecules are involved in the origin and/or
progression of esophageal cancer, including TP53 [1,2],
deleted in esophageal cancer 1(DEC1) [3], deleted in col-
orectal cancer (DCC) [4], deleted in lung cancer 1(DLC1)
[5], cyclinD1 [6,7], transforming growth factor-beta recep-
tor type II (TGFBRII) [8], adenomatous polyposis coli
(APC) [9,10], survivin [11], and murine double minute 2
(MDM2)  [12]. However, the precise mechanisms that
underlie the development and progression of esophageal
squamous cell cancer (ESCC) are far from clear. VEGF-C
has been characterized as a lymphangiogenic and angio-
genic growth factor and has been shown to signal
through the receptors VEGFR-3 (also called Flt-4) and
VEGFR-2 [13]. In this paper, we report the relationship
between the expression of VEGF-C, the clinico-patholog-
ical factors, and the prognosis of patients with ESCC.
Materials and methods
Cell lines and tissue samples
Samples were obtained from 106 patients (87 males and
19 females) with ESCC who had undergone radical
esophagectomy at the Department of Surgery II, Nagoya
City University Hospital, between 1996 and 2005. The
study design was approved by the Institutional Review
Board of our university, and written consent was
obtained from all patients. Tumors were classified
according to UICC[14]. All samples were frozen immedi-
ately in liquid nitrogen and stored at -80°C until use.
Characteristics of the 106 patients with ESCC are shown
in Table 1. The SV40-immortalized esophageal cell line
Het-1A was purchased from the American Type Culture
Collection (Manassas, VA, USA). KYSE series was
obtained from the DSMZ German Collection of Micro-
organisms and Cell Cultures (Braunschweig, Germany).
KYSE esophageal cancer cells were plated in tissue cul-
ture dishes and grown in RPMI-1640 medium (Sigma, St.
Louis, MO, USA) with 10% fetal bovine serum (JRH Bio-
science, Kansas, USA), at 37°C in a humidified atmo-
sphere of 95% air and 5% CO2. Het-1A cells were grown
in LHC-9 serum-free medium (Biofluids, Rockville, MD,
USA) in tissue culture dishes at 37°C in a humidified
atmosphere of 95% air and 5% CO2.
RNA extraction and RT-PCR analysis
Total RNA was extracted from esophageal cancer tissue,
and from corresponding noncancerous esophageal
mucosa taken from apparently normal mucosa as far
a w a y  f r o m  t h e  t u m o r  a s  p o s s i b l e ,  u s i n g  a n  I s o g e n  k i t
(Nippon Gene, Tokyo, Japan), according to the manufac-
turer's instructions. Total RNA was extracted from the
cell lines in the same way. The concentration of total RNA
was adjusted to 200 ng/ml using a spectrophotometer.
The reverse transcription reaction was performed using 1
Table 1: Relationship between clinicopathological factors 
and mRNA expression of VEGF-C
VEGF-C expression
case mean ± sd p-value
age ^65 44 -0.074 ± 0.6 0.73
< 65 62 0.16 ± 0.66
gender male 87 0.066 ± 0.65 0.06
female 19 0.037 ± 0.63
Tfactor Tis 5 -0.021 ± 0.14
T1 12 0.11 ± 0.34
T2 11 -0.098 ± 0.42
T3 33 -0.038 ± 0.7
T4 17 0.218 ± 1.0
Tis, T1 vs T2-T4 0.8
Nfactor N0 29 -0.049 ± 0.37
N1 77 0.1 ± 0.72 0.28
Stage Stage0 6 -0.23 ± 0.14
Stage1 6 -0.072 ± 0.35
Stage2A 13 -0.09 ± 0.31
Stage2B 17 0.061 ± 0.47
Stage3 30 0.085 ± 0.66
Stage4 11 -0.19 ± 1
Stage4A 23 0.34 ± 0.73
Stage0-2A vs Stage2B-4A 0.049
Histrogical Type
well 41 0.092 ± 0.57
moderate 56 0.053 ± 0.75
poor 9 -0.087 ± 0.19
well vs moderate · poor 0.34
lymphatic invasion
positive 69 0.056 ± 0.72 0.61
negative 37 0.07 ± 0.47
vein invasion
positive 54 0.024 ± 0.78 0.22
negative 52 0.098 ± 0.47
The expression of VEGF-C is higher in Stage2B-4A patients than in 
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μg of total RNA, 0.5 μg of oligo (dT) primer and Super-
script II enzyme (Gibco BRL, Gaithersburg, MD, USA),
for 60 min at 37°C, followed by 10 min 90°C and 10 min at
70°C.
TaqMan gene expression assay
Gene expression in all samples was measured by quanti-
tative RT-PCR using the Applied Biosystems 7500 Fast
Real-Time PCR System (Applied Biosystems, Foster City,
CA, USA). PCR was performed in a 20 μl reaction mix-
ture containing 10 μl TaqMan Universal PCR Master Mix
(Applied Biosystems), 80 nM of each primer, 2 nM of
probe, and 2 μl of cDNA sample. The thermal cycling
conditions included an initial denaturation step of 95°C
for 20 seconds, followed by 40 cycles at 95°C for 3 sec-
onds and annealing at 60°C for 30 seconds. Relative
mRNA expression levels were normalized to glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH). PCR prim-
ers and fluorogenic probes for the target gene and
endogenous controls were purchased from Applied Bio-
systems. The assays were supplied as a 20× mix of PCR
primers and TaqMan minor groove binder 6-FAM dye-
labeled probes with a non-fluorescent quencher at the 3'-
end of the probe. The assay numbers for GAPDH and
VEGF-C  were as follows: Hs99999905_m1 (GAPDH),
Hs01099206_m1 (VEGF-C).
Statistical analysis
Relative mRNA expression levels (log10VEGF-C/GAPDH)
were calculated from quantified data relative to the
expression level of GAPDH.  D a t a  i s  e x p r e s s e d  a s  t h e
mean ± SD. Statistical analysis was performed using the
Stat-View software package (Abacus Concepts, Berkeley,
CA, USA). Mann-Whitney U test was used to analyze the
association between mRNA expression levels and the
clinical histopathological parameters of the patients. The
survival of patients with ESCC after surgery was exam-
ined using the Kaplan-Meier method, and the survival
times were compared using the log-rank test. Univariate
analysis and multivariate analysis was performed using
the Cox's regression model. P-values were considered sig-
nificant at p < 0.05.
Results
Quantitative RT-PCR of VEGF-C in cell lines
We first investigated the expression of VEGF-C  in 12
esophageal cancer cell lines (KYSE30, KYSE50, KYSE70,
KYSE110, KYSE140, KYSE150, KYSE180, KYSE270,
KYSE410, KYSE450, KYSE510, KYSE520), and in the Het-
1A cell line. In most of the KYSE series of cell lines, espe-
cially KYSE410, high levels of VEGF-C were detected, yet
in Het-1A, VEGF-C was not detected at all (Fig. 1).
Quantitative RT-PCR of VEGF-C in clinical specimens
We next examined VEGF-C expression in 106 pairs of
resected ESCC tumors and in corresponding noncancer-
ous esophageal mucosal tissue specimens. Our data
reveals that VEGF-C  expression in cancerous tissue is
higher than in corresponding noncancerous esophageal
mucosa (Fig. 2a). We also examined the relationship
between the clinico-pathological factors and the expres-
sion of VEGF-C in ESCC. The expression of VEGF-C was
found to be higher in Stage2B-4A tumors than in Stage0-
2A tumors (Table 1, Fig. 2b). We also examined the rela-
tionship between the expression of VEGF-C and the sur-
vival data. The patients were divided into two groups
according to the expression of VEGF-C. The cut off value
was median expression of VEGF-C  (high expression
group of 53 cases and a low expression group of 53 cases).
The patients in the high VEGF-C expression group had
significantly shorter survival after surgery than the
patients in the low expression group (p = 0.0065 by log-
rank test; Fig. 3). Univariate analysis showed that, among
the clinico-pathological factors, the extent of the primary
tumor, lymph node metastasis, and high expression of
VEGF-C were all statistically significant prognostic fac-
tors (Table 2). Multivariate analysis showed that the
extent of the primary tumor and lymph node metastasis
were independent prognostic factor (Table 3).
We next analyzed a subgroup of patients with Tis and
T1 tumors (Table 4). In this subgroup, we examined the
relationship between the clinico-pathological factors and
the expression of VEGF-C in ESCC. The expression of
VEGF-C was found to be higher in N1 tumors than in N0
tumors (Table 4, Fig. 4). The expression of VEGF-C was
found to be higher in T1 and Stage2A, 2B tumors than in
Tis and Stage0-1 tumors (Table. 4). We also examined the
relationship between the expression of VEGF-C and the
survival data. The patients were divided into two groups
according to the expression of VEGF-C. The cut off value
was median expression of VEGF-C  (a high expression
group of 10 cases and a low expression group of 11 cases).
The survival rate of the patients in the high expression
Figure 1 The expression of VEGF-C in esophageal cell lines. Most 
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group was clearly lower than that in the low expression
group, and all the patients in the low VEGF-C expression
group were survived (data not shown).
Discussion
The vascular endothelial growth factor (VEGF) gene fam-
ily, which encodes five polypeptides, VEGF-A, -B, -C, -D,
and -E, is particularly important because of its angiogenic
and lymphangiogenic properties [15]. VEGF-C has been
shown to signal through the receptors VEGFR-3 (also
called Flt-4) and VEGFR-2 [13]. VEGFR-3 has also been
shown to be important in determining the potential for a
lymphangiogenic response. Recent studies have indicated
Figure 2 Comparison of mRNA expression of VEGF-C in cancer and corresponding noncancerous esophageal mucosa (a) and in Stage0-2A 
patients and Stage2B-4A patients (b). The VEGF-C expression in ESCC tumors is significantly higher than in the corresponding noncancerous esoph-
ageal mucosa (a). The VEGF-C expression is higher in Stage2B-4A patients than in Stage0-2A patients (b).
Figure 3 Survival rate of patients with ESCC according to the 
mRNA expression of VEGF-C. Patients with high expression of VEGF-
C have significantly shorter survival after surgery (p = 0.0065 by log-
rank test). The cut off value was median expression of VEGF-C
Table 2: Univariate analysis for clinicopathologic variables 
and mRNA expression of VEGF-C
parameter Riskratio 95%aCI p-value
Primary tumor
Tis, T1 1 2.11-16.13 < 0.001
T234 5.85
Lymph node metastasis
N0 1 1.66-6.9 < 0.001
N1 3.38
Lymph Invasion
Negative 1 0.98-3.11 0.056
Positive 1.75
Vein invasion
Negative 1 0.96-2.72 0.067
Positive 1.62
VEGF-C expression
Low expression 1 1.2-3.4 0.0085
High expression 2.02
aCI; confidence interval
Univariate analysis shows that, among the clinico-pathological factors, 
the extent of the primary tumor, lymph node metastasis, and high 
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that VEGFR-3 is expressed in a variety of human malig-
nancies [16]. The expression of VEGF-C and VEGFR-3
has been significantly and negatively correlated to the
progression of gastric cancer [17], cervical cancer [18],
colorectal cancer [19], and head and neck squamous cell
carcinoma [20]. In esophageal cancer, few studies have
dealt with the relationship between VEGF-C expression
and tumor progression or prognosis. Ishikawa et al inves-
tigated the expression of VEGF-C in esophageal carci-
noma, dysplasia, and normal mucosa by
immunohistochemistry. The authors reported that all
esophageal carcinomas clearly expressed VEGF-C. In
esophageal dysplasia, 82% of the cases expressed VEGF-
C. In contrast, none of the esophageal normal mucosa
expressed VEGF-C [21]. In the study by Ming-Xing Ding,
the expression of VEGF-C mRNA was higher in esopha-
geal carcinoma than in normal tissue [22]. In our study,
Table 3: Multivariate analysis for clinicopathologic 
variables and mRNA expression of VEGF-C
parameter Riskratio 95%aCI p-value
Primary tumor
Tis, T1 1 1.62-12.7 0.004
T234 4.52
Lymph node metastasis
N0 1 1.14-4.85 0.02
N1 2.36
VEGF-C expression
Low expression 1 0.97-2.78 0.065
High expression 1.64
aCI; confidence interval
Multivariate analysis shows that, among the clinico-pathological 
factors, the extent of the primary tumor and lymph node 
metastasis are statistically significant prognostic factors
Figure 4 The mRNA expression of VEGF-C in Tis and T1 ESCC tu-
mors. The expression of VEGF-C is higher in N1 tumors than in N0 tu-
mors (p = 0.029).
Table 4: Relationship between clinicopathological factors 
and mRNA expression of VEGF-C with Tis, T1tumors
VEGF-C expression
case mean ± sd p-value
age ^65 8 -0.11 ± 0.34 0.15
< 65 13 0.12 ± 0.33
gender male 19 0.06 ± 0.35 0.28
female 2 0.25 ± 0.24
Tfactor Tis 6 -0.02 ± 0.14 0.029
T1 15 0.13 ± 0.35
Nfactor N0 12 -0.15 ± 0.27
N1 9 0.27 ± 0.3 0.003
Stage Stage0 6 -0.23 ± 0.14
Stage1 6 -0.072 ± 0.35
Stage2A 1 -0.09
Stage2B 8 0.31 ± 0.29
Stage0,1 vs Stage2A,2B 0.014
Histrogical Type
well 4 0.45 ± 0.18
moderate 14 -0.1 ± 0.29
poor 3 0.092 ± 0.36
well · moderate vs poor 0.69
lymphatic invasion
positive 7 0.006 ± 0.39
negative 14 -0.04 ± 0.34 0.77
vein invasion
positive 3 0.053 ± 0.51
negative 18 0.025 ± 0.33 > 0.99
The expression of VEGF-C is higher in T1, N1 and Stage2A, 2B tumors 
than in Tis, N0 and Stage0,1 tumorsTanaka et al. Journal of Experimental & Clinical Cancer Research 2010, 29:83
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most of the KYSE cell lines expressed VEGF-C, the SV40-
immortalized esophageal cell line Het-1A did not express
VEGF-C mRNA, and the expression of VEGF-C in can-
cerous tissue was higher than in corresponding noncan-
cerous esophageal mucosa. This suggests that VEGF-C
may play an important role in tumor progression. Oka-
zawa et al. reported that VEGF-C expression correlated
with the depth of tumor invasion, lymphatic invasion,
and lymph node metastasis in esophageal cancer. They
also claimed that the prognosis was significantly worse
for patients with tumors positive for VEGF-C than for
those with tumors negative for VEGF-C, and that VEGF-
C expression was an independent prognostic determinant
[23]. The discrepancy between their report and present
study may be from methodology. They investigated 100
tumors by immunohistochemistry, and treated 43% of
VEGF-C positive cases.
Esophageal carcinoma most likely metastasizes in
lymph node, which correlates with the prognosis of the
patients. In this study, the expression of VEGF-C mRNA
correlates with lymph node metastasis, and the patients
with high VEGF-C-expressing tumors have a poorer
prognosis than those with low VEGF-C-expressing
t u m o r s .  T o  a v o i d  h i g h l y  i n v a s i v e  s u r g e r y ,  E M R ,  E S D ,
chemoradiotherapy, and their combinations have been
indicated for patients with early esophageal cancers. In
the non-surgical treatment of early esophageal cancer, a
high rate of local recurrence and lymph node metastasis
is evident [24]. For non-surgical treatment, particularly
ESD and EMR, preoperative diagnosis of lymph node
metastasis is essential. However, the accuracy of diagno-
sis of lymph node metastasis by computed tomography is
reported to be 11-38%, endoscopic ultrasound 75-76%,
and positron emission tomography 30-52% [25-28]. The
sensitivity of endoscopic ultrasound is high, yet it does
not detect distant metastases [26]. For the decision of
non-surgical treatment, the sensitivity is just not high
enough. Our study shows that expression of VEGF-C cor-
relates with lymph node metastasis, and negatively corre-
lates with survival in early squamous cell carcinoma. If
early esophageal cancer expresses high VEGF-C, the
patients have increased risk of lymph node metastasis
and thus, a poor prognosis. Hence, the expression of
VEGF-C  may assist in the diagnosis of lymph node
metastasis for esophageal superficial carcinoma.
Although the precise molecular mechanisms of up-regu-
lated VEGF-C expression need to be clarified, our data
suggests that VEGF-C is a good candidate as a molecular
prognostic marker as well as a molecular target for the
development of effective treatment for patients with
esophageal cancer.
Conclusions
The expression of VEGF-C correlates with lymph node
metastasis and poor prognosis. In patients with Tis and
T1 esophageal tumors, the expression of VEGF-C may be
a good diagnostic factor for determining metastasis of the
lymph node.
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